Skip to main content

Eisai

Eisai Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription drugs globally. The company operates primarily through its oncology and neurology business segments, focusing on complex diseases. Key products include targeted oncology treatments such as lenvatinib and therapeutic treatments for Alzheimer's disease such as lecanemab. Primary revenue drivers include sales of proprietary prescription pharmaceuticals across major geographic regions, including Japan, the United States, Europe, and Asia. Eisai holds a significant global market position, particularly within neurodegenerative disease therapeutics. The company is headquartered in Tokyo, Japan, and its shares are listed on the Tokyo Stock Exchange.

28 of the funds FundTelligence covers report a position in Eisai.

Sector
Health Care
Country
Japan
Funds holding it
28
Exposure themes
Ageing & Longevity, Age-Related Disease, Neurodegeneration

Funds holding Eisai

Showing the 8 largest of 28 funds holding it.

Loading...